Biomarker in Tissue Samples From Patients With Ewing Sarcoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT01365949
First received: June 1, 2011
Last updated: June 4, 2011
Last verified: June 2011

June 1, 2011
June 4, 2011
May 2011
August 2011   (final data collection date for primary outcome measure)
Frequency of INI1 protein loss in Ewing Sarcoma [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01365949 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Biomarker in Tissue Samples From Patients With Ewing Sarcoma
INI-1 Deletions in Ewing Sarcoma

RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This research trial studies biomarkers in tissue samples from patients with Ewing sarcoma.

OBJECTIVES:

  • To determine the frequency of INI-1 protein loss in Ewing Sarcoma.

OUTLINE: Previously collected tissue samples are analyzed for INI-1 protein loss by IHC and tissue microarray.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Sarcoma
  • Genetic: microarray analysis
  • Genetic: protein analysis
  • Other: immunohistochemistry staining method
  • Other: laboratory biomarker analysis
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
40
Not Provided
August 2011   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of Ewing sarcoma
  • Prepared tissue microarray with Ewing sarcoma samples available

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01365949
CDR0000701010, COG-AEWS11B1
Not Provided
Gregory H. Reaman, Children's Oncology Group - Group Chair Office
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Joshua D. Schiffman, MD University of Utah
National Cancer Institute (NCI)
June 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP